CHICAGO — Osimertinib following chemoradiotherapy drastically improved PFS compared with placebo in patients with advanced EGFR-mutant non-small cell lung cancer in a randomized phase 3 trial.
Blinded independent review and study investigators separately determined a greater than 80% risk reduction for those treated with the osimertinib-based regimen, according to results presented at ASCO Annual Meeting.
“When we saw the hazard ratio, we were very excited because it exceeded our expectations,” Suresh S. Ramalingam, MD, FACP, FASCO, executive director of Winship Cancer